US patent office approves Dicotyledon patent for libiguin synthesis

Uppsala, Sweden, 15 April 2016

The US patent office today told that Dicotyledon patent "Novel compounds, their manufacture and use in synthesis" covering the chemical synthesis of the libiguins will be granted in USA.

The patent covers a method for synthesis of the libiguins allowing their production in commercial quantities.

As libiguins are available only in small quantities naturally the ability to afford them by synthesis is an important step towards the development of libguins as prescription drugs for broad markets, says Dicotyledon CEO Jarl Wikberg.